ADMA - ADMA Biologics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

935.6M

Cash

69.2M

Avg Qtr Burn

-12.05M

Short % of Float

5.27%

Insider Ownership

2.51%

Institutional Own.

73.90%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BIVIGAM® Details Autoimmune disease, Immunodeficiency, Primary humoral immunodeficiency	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ASCENIV™ Details Immunodeficiency, Autoimmune disease, Primary humoral immunodeficiency	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nabi-HB® Details HB (Hepatitis B)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.